Its valuation is considered fairly valued, Institutional ownership is very high.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gelteq Ltd's Score
Industry at a Glance
Industry Ranking
136 / 173
Overall Ranking
564 / 4682
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Gelteq Ltd Highlights
StrengthsRisks
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
Overvalued
The company’s latest PE is -2.15, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 105.80K shares, increasing 0.61% quarter-over-quarter.
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
Ticker SymbolGELS
CompanyGelteq Ltd
CEOGivoni (Nathan Jacob)
Websitehttps://www.gelteq.com
FAQs
What is the current price of Gelteq Ltd (GELS)?
The current price of Gelteq Ltd (GELS) is 0.897.
What is the symbol of Gelteq Ltd?
The ticker symbol of Gelteq Ltd is GELS.
What is the 52-week high of Gelteq Ltd?
The 52-week high of Gelteq Ltd is 4.110.
What is the 52-week low of Gelteq Ltd?
The 52-week low of Gelteq Ltd is 0.770.
What is the market capitalization of Gelteq Ltd?
The market capitalization of Gelteq Ltd is 9.61M.
What is the net income of Gelteq Ltd?
The net income of Gelteq Ltd is -6.65M.
Is Gelteq Ltd (GELS) currently rated as Buy, Hold, or Sell?
According to analysts, Gelteq Ltd (GELS) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Gelteq Ltd (GELS)?
The Earnings Per Share (EPS TTM) of Gelteq Ltd (GELS) is -1.070.